Melioidosis News and Research

RSS

UCLA researchers develop promising vaccine against deadly melioidosis bacterium

In a mouse study, UCLA researchers tested a vaccine against the bacterium that causes melioidosis and found it was highly protective against the disease, which is endemic in many tropical areas, causing approximately 165,000 cases with 89,000 fatalities around the world each year.

22 Mar 2024

Rapid, easy-to-use diagnostic test could save more lives from melioidosis

Globally, more than half of patients die after infection with the neglected tropical disease, melioidosis, often before they are diagnosed.

13 Mar 2024

Genomic sequencing: A key tool for responding to pandemics

Many of the answers for effectively responding to a pathogen lie in its genome.

1 Aug 2023

Study reveals potential bioterrorism agents and urges enhanced biosecurity measures

Research paper provides pathogen incidences for potential bioterrorism agents in the Netherlands from 2009 to 2019. The study highlights the need for biosecurity measures based on the observed incidences.

15 Jun 2023

LLNL licensee and collaborators develop novel medicines to combat autoimmune diseases

People afflicted with autoimmune diseases may someday receive help through treatments now under development by a Lawrence Livermore National Laboratory licensee and its' collaborations with two major pharmaceutical companies.

17 Feb 2023

Isolation of Burkholderia thailandensis from the environment

A new study in Emerging Infectious Diseases aimed to detect and isolate B. thailandensis from water and soil samples collected from Puerto Rico between December 2018 and March 2020 as well as Texas between November 2019 to November 2020.

15 Feb 2023

CDC and Task Force for Global Health to co-host 11th International Conference on Emerging Infectious Diseases

The Centers for Disease Control and Prevention and the Task Force for Global Health will co-host in person the 11th International Conference on Emerging Infectious Diseases August 7-10, 2022, at the Hyatt Regency Atlanta hotel in Atlanta, GA.

9 Aug 2022

CDC identifies bacteria that cause rare melioidosis in domestic environmental samples

The Centers for Disease Control and Prevention (CDC) has identified for the first time in domestic environmental samples the bacteria that causes a rare and serious disease called melioidosis.

8 Aug 2022

Researchers discover new family of sensing genes in enteric bacteria using AI

Using artificial intelligence, UT Southwestern researchers have discovered a new family of sensing genes in enteric bacteria that are linked by structure and probably function, but not genetic sequence.

30 Jun 2022

INRS professor developing a glycoconjugate vaccine for melioidosis

The threat from Melioidosis is real. The bacterium that causes this infectious multisymptom illness is resistant to antibiotics, making diagnosis and treatment more complex and resulting in a mortality rate of up to 50%.

24 Mar 2022

Poolbeg and University College Dublin sign an Option Agreement to license melioidosis vaccine candidate

Poolbeg Pharma, 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin and its inventor, Associate Professor Siobhán McClean, through NovaUCD, the university's knowledge transfer office.

7 Dec 2021

CDC: Cause of melioidosis outbreak confirmed

The Centers for Disease Control and Prevention today confirmed that bacteria in a Better Homes & Gardens aromatherapy spray in a Georgia melioidosis patient's home genetically matches the bacterial strains in the patient, and three other patients in Kansas, Minnesota, and Texas infected since March.

30 Oct 2021

CDC lab testing identifies deadly bacteria in an aromatherapy spray

Laboratory testing at the U.S. Centers for Disease Control and Prevention (CDC) has identified the bacteria Burkholderia pseudomallei in an aromatherapy spray -; the same type of bacteria that sickened four people in the United States earlier this year.

22 Oct 2021

VALIDATE Network’s TB vaccine work receives $1.5 million funding boost

The Oxford-run VALIDATE Network has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation.

23 Aug 2021

Researchers develop mathematical model for monitoring, controlling spread of melioidosis

An international research team from the University of Leicester, Lomonosov Moscow State University, and the Moscow Institute of Physics and Technology from Russia has developed a mathematical model for monitoring and controlling the spread of melioidosis in Southeast Asia.

12 Sep 2018

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

A biopharmaceutical company collaborating with Hawai'i scientists on an Ebola vaccine announced encouraging news about its vaccine today.

19 Jul 2016

Deadly bacteria can travel to the brain and spinal cord in 24 hours, new study finds

A deadly bacteria that can be picked up by a simple sniff can travel to the brain and spinal cord in just 24 hours, a new Griffith University and Bond University study has found.

11 Jul 2016

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).

27 Aug 2015